Tang Capital Management
Latest statistics and disclosures from Tang Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are AUPH, SYRE, MIRM, KNSA, CELC, and represent 37.07% of Tang Capital Management's stock portfolio.
- Added to shares of these 10 stocks: NVCT (+$29M), CELC (+$28M), TARS (+$24M), FULC (+$24M), NNDM (+$21M), CAPR (+$17M), CMPS (+$14M), AUPH (+$14M), Gossamer Bio (+$12M), BOLD (+$6.4M).
- Started 5 new stock positions in NVCT, BOLD, FULC, NNDM, Gossamer Bio.
- Reduced shares in these 10 stocks: Kalvista Pharmaceuticals (-$92M), SPY (-$34M), INSM (-$17M), JANX (-$7.0M), STOK (-$6.5M), , URGN (-$6.3M), ARVN (-$5.7M), Kezar Life Sciences, MRNA.
- Sold out of its positions in ABEO, AGIO, ARVN, BIIB, CHRS, ERAS, EOLS, FATE, JANX, Kalvista Pharmaceuticals. Kezar Life Sciences, LXRX, NMRA, NKTX, URGN.
- Tang Capital Management was a net seller of stock by $-12M.
- Tang Capital Management has $2.2B in assets under management (AUM), dropping by 11.82%.
- Central Index Key (CIK): 0001232621
Tip: Access up to 7 years of quarterly data
Positions held by Tang Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Tang Capital Management
Tang Capital Management holds 41 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Aurinia Pharmaceuticals (AUPH) | 10.1 | $221M | +6% | 13M | 16.97 |
|
| Spyre Therapeutics Com New (SYRE) | 7.6 | $168M | 1.9M | 88.78 |
|
|
| Mirum Pharmaceuticals (MIRM) | 6.6 | $145M | 1.2M | 117.07 |
|
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 6.6 | $145M | 2.3M | 63.95 |
|
|
| Celcuity (CELC) | 6.2 | $138M | +25% | 1.3M | 104.62 |
|
| Corcept Therapeutics Incorporated (CORT) | 5.9 | $130M | 1.5M | 86.95 |
|
|
| Ptc Therapeutics I (PTCT) | 5.6 | $122M | 1.5M | 81.57 |
|
|
| Lakefront Biotherapeutics Nv Spon Adr | 5.2 | $114M | 3.8M | 29.98 |
|
|
| Capricor Therapeutics Com New (CAPR) | 4.5 | $99M | +20% | 4.1M | 24.08 |
|
| Tarsus Pharmaceuticals (TARS) | 4.5 | $99M | +31% | 1.6M | 62.94 |
|
| State Str Spdr S&p 500 Etf T Tr Unit (SPY) | 4.2 | $92M | -26% | 123k | 746.77 |
|
| Anaptysbio Inc Common (ANAB) | 4.1 | $90M | 1.3M | 67.50 |
|
|
| Immunocore Hldgs Ads (IMCR) | 3.8 | $84M | 2.6M | 31.75 |
|
|
| Compass Pathways Sponsored Ads (CMPS) | 3.2 | $71M | +24% | 5.0M | 14.15 |
|
| Biosante Pharmaceuticals (ANIP) | 2.7 | $59M | 708k | 82.78 |
|
|
| Biontech Se Sponsored Ads (BNTX) | 2.0 | $44M | 470k | 93.05 |
|
|
| Compass Therapeutics (CMPX) | 1.8 | $39M | +7% | 18M | 2.19 |
|
| Precigen (PGEN) | 1.7 | $37M | 6.4M | 5.70 |
|
|
| Miragen Therapeutics (VRDN) | 1.5 | $33M | 1.8M | 18.37 |
|
|
| Nuvectis Pharma (NVCT) | 1.3 | $29M | NEW | 1.6M | 18.39 |
|
| Dianthus Therapeutics (DNTH) | 1.2 | $26M | 265k | 97.48 |
|
|
| Fulcrum Therapeutics (FULC) | 1.1 | $24M | NEW | 6.5M | 3.66 |
|
| Atea Pharmaceuticals (AVIR) | 1.0 | $22M | 4.8M | 4.65 |
|
|
| Crescent Biopharma (CBIO) | 0.9 | $21M | 1.2M | 18.00 |
|
|
| Nano Dimension Sponsord Ads New (NNDM) | 0.9 | $21M | NEW | 14M | 1.45 |
|
| Viking Therapeutics (VKTX) | 0.9 | $20M | 500k | 39.01 |
|
|
| Nuvation Bio Com Cl A (NUVB) | 0.9 | $19M | +4% | 3.3M | 5.68 |
|
| Ideaya Biosciences (IDYA) | 0.8 | $17M | 450k | 37.27 |
|
|
| Gossamer Bio Note 5.000% 6/0 (Principal) | 0.5 | $12M | NEW | 18M | 0.64 |
|
| Journey Med Corp (DERM) | 0.5 | $11M | 1.6M | 7.08 |
|
|
| Insmed Com Par $.01 (INSM) | 0.5 | $11M | -61% | 100k | 106.62 |
|
| Stoke Therapeutics (STOK) | 0.4 | $9.8M | -40% | 300k | 32.72 |
|
| Pliant Therapeutics (PLRX) | 0.3 | $7.0M | 6.1M | 1.14 |
|
|
| Boundless Bio (BOLD) | 0.3 | $6.4M | NEW | 2.6M | 2.50 |
|
| Pmv Pharmaceuticals (PMVP) | 0.3 | $5.7M | 4.2M | 1.34 |
|
|
| Moderna (MRNA) | 0.2 | $3.5M | -50% | 50k | 70.03 |
|
| Wave Life Sciences SHS (WVE) | 0.2 | $3.5M | 600k | 5.81 |
|
|
| Heron Therapeutics (HRTX) | 0.1 | $2.7M | 6.3M | 0.43 |
|
|
| Lenz Therapeutics (LENZ) | 0.1 | $2.6M | 451k | 5.68 |
|
|
| Altimmune Com New (ALT) | 0.1 | $2.0M | 666k | 3.04 |
|
|
| Rocket Pharmaceuticals (RCKT) | 0.0 | $342k | 100k | 3.42 |
|
Past Filings by Tang Capital Management
SEC 13F filings are viewable for Tang Capital Management going back to 2011
- Tang Capital Management 2026 Q2 filed Aug. 14, 2026
- Tang Capital Management 2026 Q1 filed May 15, 2026
- Tang Capital Management 2025 Q4 filed Feb. 17, 2026
- Tang Capital Management 2025 Q3 filed Nov. 14, 2025
- Tang Capital Management 2025 Q2 filed Aug. 14, 2025
- Tang Capital Management 2025 Q1 filed May 15, 2025
- Tang Capital Management 2024 Q4 filed Feb. 14, 2025
- Tang Capital Management 2024 Q3 filed Nov. 14, 2024
- Tang Capital Management 2024 Q2 filed Aug. 14, 2024
- Tang Capital Management 2024 Q1 filed May 15, 2024
- Tang Capital Management 2023 Q4 filed Feb. 14, 2024
- Tang Capital Management 2023 Q3 filed Nov. 14, 2023
- Tang Capital Management 2023 Q2 filed Aug. 14, 2023
- Tang Capital Management 2023 Q1 filed May 15, 2023
- Tang Capital Management 2022 Q4 filed Feb. 14, 2023
- Tang Capital Management 2022 Q3 filed Nov. 14, 2022